Article

IPO positions Alcon for tomorrow

Author(s):

Mark L. Dlugoss

Fort Worth, TX-Amid the fanfare of the New York Stock Exchange and company executives, Tim Sear of Alcon Laboratories Inc. and Peter Brabeck-Letmathe of Nestl? A stood atop the balcony overlooking the trading floor and rang the opening bell, marking the official start of the day on Wall Street.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
(Image credit: Ophthalmology Times) The Residency Report: Clinical insights from the iStent infinite trial
(Image credit: Ophthalmology Times) ASCRS 2025: Amar Shah, MD, on why hyperosmolar tear film before and after cataract surgery matters
Related Content
Q&A: David S. Boyer, MD, on the suprachordial delivery of gene therapy
June 5th 2025

Q&A: David S. Boyer, MD, on the suprachordial delivery of gene therapy

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Ocugen signs term sheet for korean licensing of OCU400 gene therapy
June 5th 2025

Ocugen signs term sheet for korean licensing of OCU400 gene therapy

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

iVeena submits IND to FDA for phase 2 clinical trial for pediatric myopia
June 4th 2025

iVeena submits IND to FDA for phase 2 clinical trial for pediatric myopia

(Image credit: AdobeStock/RFBSIP) The impact of preservatives on the ocular surface in patients with ocular hypertension or glaucoma
June 4th 2025

The impact of preservatives on the ocular surface in patients with ocular hypertension or glaucoma

© 2025 MJH Life Sciences

All rights reserved.